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Background/aim: Evidence suggests that the risk for dementia increases after stroke. This study investigated the dynamics of the
neurological and cognitive status of patients with no baseline dementia over a 1-year period after ischemic stroke.
Materials and methods: We examined 47 ischemic stroke patients admitted within 48 h of ictus. Their neurological and cognitive
statuses, blood biochemical parameters, and microalbuminuria levels were prospectively evaluated over a 1-year period post-stroke.
Results: A more severe neurological deficit was found in the cognitively impaired patients (P = 0.003). The NIHSS score over a 1-year
follow-up period improved only in patients with normal cognition (P = 0.000). Time-varying dynamics of the MMSE score were
observed in both patient groups (P = 0.000). Age (Р = 0.000), education (Р = 0.004), sex (Р = 0.041), history of diabetes (Р = 0.045),
and serum high sensitive C-reactive protein (hs-CRP) on admission (Р = 0.003) were significant determinants of cognitive decline 1
year after a stroke. The albumin-to-creatinine ratio was high during the whole follow-up period in the cognitively impaired group after
adjusting for sex and age (P = 0.010). Binary logistic regression showed that hs-CRP (Р = 0.013) and age (Р = 0.010) were independent
predictors of patients’ cognitive status 1 year after stroke.
Conclusion: The level of inflammatory markers could be considered as an additional criterion of long-term cognitive impairment.
Key words: Cognitive impairment, hs-CRP, ischemic stroke, long-term prognosis, endothelial dysfunction

1. Introduction
Stroke survivors display a variety of disabling symptoms
such as motor deficit, sensory disorders, and aphasia
that have been widely discussed in the medical literature.
Limited studies have focused on poststroke cognitive
dysfunctions (1,2). Although patients may physically
fully recover after a stroke, they often remain unable to
live independently due to poor cognitive status. Even
patients with only mild poststroke cognitive deficits can
have substantial disability and are at an increased risk of
cognitive deterioration. Untouched opportunities still
exist for prevention and treatment.
The reported incidence of cognitive decline within the
first month after stroke varies significantly depending on
the definition of deficit and the patient selection criteria.
Despite the ability of the brain to compensate for tissue
impairment, which can result in cognitive improvement,
most patients show little progress and develop long-term
cognitive deterioration. The poststroke cognitive decline
mechanisms in the chronic phase of cerebral ischemia are
still insufficiently investigated.
* Correspondence: margalexandrova@hotmail.com
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Research shows that stroke increases the risk for
cognitive impairment regardless of demographic and
vascular risk factors (3,4). An association exists between
cognitive dysfunction and lesion localization (5). Factors
such as stroke characteristics (dysphasia and dominant
syndromes) and previous vascular events independently
increase the risk for cognitive injury (2). Some vascular
risk factors, including history of diabetes, hypertension,
and TIA, are also closely related to cognitive deterioration
in the subacute and chronic phases of stroke (6). The
importance of these factors stems from the fact that they
predispose to cognitive decline even in the absence of a
previous stroke.
The role of inflammatory mechanisms and endothelial
dysfunction in poststroke cognitive impairments has not
been extensively studied (6). Limited data have shown
that elevated levels of some inflammatory markers in the
circulation of ischemic stroke patients imply a lower grade
of poststroke global cognition (7).
The present study was performed in an attempt to
examine:
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■ The dynamics of the neurological and cognitive
status of patients with no baseline dementia over
a 1-year period after ischemic stroke.
■ The dynamics of peripheral leukocytes, lipid
profile components, and microalbuminuria
over a 1-year period after ischemic stroke and
the difference in these parameters between
cognitively normal and cognitively impaired
patients.
■ Independent predictors of cognitive decline in
the first year following stroke.
2. Materials and methods
2.1. Study population
Out of 63 ischemic stroke patients admitted to the
Department of Neurology, University Hospital in Pleven,
Bulgaria, from October 2006 through April 2009, we
selected 47 (26 men and 21 women). The study did not
include individuals with a history of acute or chronic
infection, cancer, kidney or liver disease, or preceding
surgical intervention. Additional exclusion criteria were
the presence of subarachnoid or intracerebral hemorrhage,
the absence of a CT scan of the brain at admission,
prestroke dementia, and neurological or psychiatric
disorders that can cause cognitive dysfunction. The
patients were screened for depression using the Hamilton
Depression Rating Scale (8), and those with depression
were also excluded from the study.
A detailed questionnaire assessing the medical
history and physical state of the patients was filled out
by an experienced neurologist. Arterial hypertension
was defined as mean systolic pressure >140 mmHg and
mean diastolic pressure >90 mmHg. Diabetes mellitus was
defined as a blood glucose level of >7.1 mmol/L.
All experiments were conducted in accordance with
the rules and regulations approved by the University
Research Ethics Committee.
2.2. Neurological examination
National Institutes of Health Stroke Scale (NIHSS) and
the modified Rankin Scale (mRS) scores were used to
determine the neurological deficit and clinical outcome,
respectively, at discharge and at 3, 6, and 12 months
following the stroke. Cognitive status was evaluated by
the Mini Mental State Examination (MMSE) score (the
maximum score of the MMSE can be 30 points; a lower
score is an indication of impaired cognition). For repeated
measure analysis and binary logistic regression, the
cognitive status in the first year after stroke was represented
by a dichotomous variable indicating “normal cognition”
(coded 0) if the MMSE score was ≥24 points or “cognitive
deficit” (coded 1) if the MMSE score was <24 points.

2.3. Biochemical tests
Peripheral venous blood and morning spot- and 24-h
urine samples were collected at admission and at 3, 6,
and 12 months after stroke. Blood biochemistry was
studied using standard methods. The collected sera were
stored at –20 °C until assayed. The serum level of high
sensitive C-reactive protein (hs-CRP) was measured
by a turbidimetric method on admission (9). Urinary
albumin and creatinine were measured using the Cobas
Integra system (Roche Diagnostics). Urinary albumin was
measured by the immunoturbidimetric method. Urinary
creatinine was measured by the kinetic Jaffe reaction (10).
2.4. Statistical analysis
Statistical analysis was performed with SPSS 19.0 (SPSS
Inc., Chicago, IL, USA). Pearson chi-square or Fisher exact
tests were used to compare proportions between patient
groups. The interval variables were represented as mean
(±standard deviation) or median (25th–75th percentile),
depending on the type of distribution.
Normality of distribution was checked with the
Shapiro–Wilk test. The significance of differences
between groups was assessed using the Student t-test
and one-way ANOVA for normally distributed data,
along with the Mann–Whitney U test and the Kruskal–
Wallis test for nonparametric data. Spearman or Pearson
product moment correlations were used to examine the
relationships between clinical and biochemical parameters.
Two approaches were applied to study the dynamics
of neurological and cognitive status and the biochemical
parameters over the 1-year poststroke period. For
normally distributed data, general linear model repeated
measures analysis with the univariate test of withinsubjects effects was used. In the case of violation of the
sphericity assumption, the adjusted P-values given by the
Greenhouse–Geisser correction were applied. Bonferroni
correction for multiple comparisons was made for
P-values. For nonparametric data, the Friedman test was
carried out. Post hoc analysis with Wilcoxon signed-rank
tests was conducted with Bonferroni correction, resulting
in a significance level set at P < 0.0083 (for 4 levels and 6
pairwise comparisons). A log transformation was applied
to obtain normal distribution of data in most cases.
A binary logistic regression model was built to assess
the predictive value of statistically significant factors on the
dichotomous dependent variable “cognitive status 1 year
after stroke”. The calibration of the model, or the extent to
which the observed and predicted probabilities matched,
was evaluated by a Hosmer–Lemeshow goodness-offit test. The discrimination ability of the model, i.e. the
capacity to differentiate patients with cognitive impairment
from those with normal cognition, was assessed with
receiver operating characteristic (ROC) curve analysis by
calculating the area below the ROC curves. A value of P <
0.05 was considered statistically significant.
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3. Results
3.1. Basic characteristics of the study population
The basic characteristics of the study population and the
potential factors affecting cognition in the first year after
stroke are given in Table 1. Twenty-six (55%) of the 47
patients were males. The age of the participants varied from
56 to 76 years (median: 63). Localization of the infarction
was as follows: left hemisphere - 21 patients (frontal -9;
parietal - 8; thalamic - 1; capsular - 3); right hemisphere 21 patients (frontal - 8; parietal - 4; thalamic - 3; capsular
- 6), and stem - 5 patients. Forty-three percent of the
patients showed mild to moderate cognitive impairment,
and 34% were at risk for developing cognitive deficit 1 year
after stroke.
Age, sex, level of education, history of diabetes, WBC
count in the first year after stroke, and serum hs-CRP level
at hospital admission were significant factors for cognitive
deterioration 1 year after stroke (Table 1).
3.2. Dynamics of neurological and cognitive status
Significant time variations in the NIHSS scores over a
1-year period were found in the cognitively intact patients
(χ2(3) = 23.071, P = 0.000) (Figure 1A). Furthermore, their
neurological statuses gradually improved, and a significant
difference was reached between the admission scores and
the third-month scores (Z = –2.900, P = 0.004), and between
the admission scores and the 1-year scores (Z = –2.641,
P = 0.008). No significant time variations in the NIHSS
scores over a 1-year period were found for the cognitively
impaired group (χ2(3) = 0.931, P = 0.818). The neurological
deficit severity was higher in the cognitively impaired than
in the cognitively normal subjects (χ2(3) = 13.748, P =
0.003). Time-varying dynamics of the MMSE score were
observed in both the cognitively normal (χ2(3) = 25.358,
P = 0.000) and cognitively impaired (χ2(3) = 45.816, P =
0.000) groups (Figure 1B). Cognition deteriorated within
a 3-month period in patients who remained cognitively
intact at 1 year post stroke (discharge/3rd month, Z
= –3.598, P = 0.000). Cognition deteriorated within 6
months in the cognitively impaired patients and became
stationary afterwards (discharge/3rd month, Z = –3.571, P
= 0.000; and 3rd month/6th month, Z = –2.953, P = 0.003).
3.3. Dynamics of peripheral leukocyte count, lipid profile
components, and microalbuminuria
A temporal profile of WBC count towards reduction was
found for both cognitively normal (χ2(3) = 20.309, P =
0.000) and cognitively impaired (χ2(3) = 10.484, P = 0.015)
patients (Figure 1C). A difference between separate points
in time was established only for the cognitively normal
group (admission/3rd month, Z = –2.646, P = 0.008; 3rd
month/6th month, Z = –2.823, P = 0.005; 6th month/1st
year, Z = –2.796, P = 0.005; and admission/1st year, Z =
–3.354, P = 0.001). The WBC count was higher in the
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cognitively impaired as compared with the cognitively
intact group within the whole 1-year period (χ2(1) = 6.167,
P = 0.013).
The granulocytes were the only cells responsible for the
observed difference in the WBC count between the two
patient groups since statistical significance was reached
only for them (inset in Figure 1C). The Greenhouse–
Geisser test did not show any time dependence in the
granulocyte count (F = 2.919, P = 0.078) in either group.
The granulocyte count was persistently higher in the
cognitively impaired than in the cognitively intact patients
(F = 8.205, P = 0.006). The difference remained significant
after adjusting for sex and age (F = 7.042, P = 0.011).
No significant time variations and differences were
found between the groups in the lipid profile components
(total cholesterol, LDL, HDL, TG, LDL/HDL, and
cholesterol/HDL). The albumin-to-creatinine ratio was
higher in the cognitively impaired group (F = 7.134, P
= 0.010), and the difference remained significant after
adjusting for sex and age (F = 4.408, P = 0.042) (Figure
1D). No significant time variations were observed in either
group (F = 2.525, P = 0.117).
3.4. Independent predictors of cognitive decline at 1 year
after stroke
We created a binary logistic regression model to identify
the independent predictors of the 1-year cognitive decline.
The cognitive status in the model was represented as a
dichotomous outcome variable. The explanatory variables
included two demographic factors (sex and age), an
inflammatory marker (hs-CRP), and a vascular risk factor
(history of diabetes), thus meeting the requirement for the
ratio of the number of events per variable to be greater
than 10.
Education was excluded from the model because of an
insufficient number of cases observed in some subgroups.
The WBC count measured in the first year post stroke was
also excluded since an inflammatory marker had already
been introduced in the model.
The existence of a relationship between the
dichotomous outcome variable and the combination of
independent variables was confirmed by the statistical
significance of the block chi-square (χ2 = 31.009, Р =
0.000). Wald statistics showed that age (P = 0.010) and hsCRP (P = 0.013) were significant predictors of cognitive
decline (Table 2). Furthermore, an increase by 1 year in age
and by 1 mg/L in hs-CRP resulted in a 30.9% and 18.9%
increase in odds of cognitive decline in the first year after
stroke, respectively. Nagelkerke R2 analysis showed that
about 65% of the variation in the cognitive status could be
explained by this logistic model. The Hosmer–Lemeshow
goodness-of-fit measure confirmed that the entire model
matched the observed values (χ2 =2.777, P = 0.905). The
area under the ROC curve, used to assess the model’s
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Table 1. Characteristics and potential factors associated with cognitive status 1 year after stroke.
Cognitive status 1 year post stroke

Parameters

All patients
(n = 47)

Age [years], median (25th–75th)

63

(59–69)

58

Male sex, n (%)

26

(55)

8th grade

9

High school

24

Normal
(n = 11)

Risk of deficit
(n = 16)

Mild to moderate deficit
(n = 20)

P-value

(57–59)

64

(60–69)

67

(63–71)

0.000*

9

(81)

10

(63)

7

(35)

0.041*

(19)

0

(0)

3

(19)

6

(30)

(51)

3

(27)

8

(50)

13

(65)

Education, n (%)

0.004*

College

5

(11)

4

(36)

1

(6)

0

(0)

University

9

(19)

4

(36)

4

(81)

1

(5)

Vascular risk factors
Arterial hypertension, n (%)

45

(96)

9

(82)

16

(100)

20

(100)

0.051

Systolic blood pressure [mmHg], (SD)

158

(29)

143

(28)

161

(23)

164

(33)

0.150

Diastolic blood pressure [mmHg], (SD)

95

(16)

90

(13)

95

(19)

97

(15)

0.603

Diabetes mellitus, n (%)

13

(28)

0

(0)

6

(38)

7

(35)

0.045*

Alcohol abuse, n (%)

10

(21)

4

(36)

2

(13)

4

(20)

0.308

Cigarette smoking, n (%)

19

(40)

6

(54)

7

(44)

6

(30)

0.379

History of stroke, n (%)

10

(21)

3

(27)

3

(19)

4

(20)

0.814

NIHSS score 1*, median (25th–75th)

5

(4–6)

5

(2–7)

4

(3–5)

5

(4–7)

0.130

NIHSS score 2, median (25th–75th)

3

(2–5)

2

(0–3)

2

(1–4)

3

(2–12)

0.035*

mRS score , median (25th–75th)

1

(1–2)

1

(1–2)

1

(1–2)

2

(1–2)

0.463

mRS score , median (25th–75th)

1

(1–2)

1

(0–1)

1

(0–1)

1

(1–3)

0.180

Neurological examination

1*
2

Radiological variables
Localization, n (%)

0.126

Hemispherical

39

(83)

8

(73)

13

(81)

18

(90)

Lacunar

3

(6)

0

(0)

1

(6)

2

(10)

Stem

5

(11)

3

(27)

2

(13)

0

(0)

WBC1 [×109/L], (SD)

7.8

(1.7)

7.0

(1.3)

7.7

(1.3)

8.3

(2.1)

0.154

WBC [×10 /L], (SD)

7.6

(1.9)

6.6

(1.4)

7.3

(1.5)

8.3

(7.7)

0.043*

Biochemistry

2

9

Glucose [mmol/L], median (25th–75th)

5.5

(5.1–6.8)

5.2

(4.7–5.5)

6.3

(5.3–7.2)

5.5

(5.2–6.8)

0.093

Glucose2 [mmol/L], median (25th–75th)

5.6

(5.4–6.6)

5.8

(5.5–6.3)

5.6

(5.3–7.0)

5.7

(5.4–6.7)

0.857

Cholesterol1 [mmol/L], median (25th–75th)

5.1

(4.5–5.6)

5.0

(4.4–5.5)

4.7

(4.4–5.2)

4.9

(4.7–5.6)

0.226

Cholesterol2 [mmol/L], median (25th –75th)

5.1

(4.5–5.8)

5.1

(4.5–5.9)

4.9

(4.7–5.6)

5.2

(4.5–6.1)

0.964

TG1 [mmol/L], median (25th –75th)

1.7

(1.3–2.0)

1.6

(1.2–2.1)

1.5

(1.3–2.1)

1.7

(1.3–2.0)

0.865

1

TG [mmol/L], median (25th –75th)

1.4

(1.4–2.0)

1.7

(1.0–1.7)

1.3

(1.0–1.8)

1.9

(1.2–2.6)

0.087

hs-CRP1 [mg/L], median (25th –75th)

2.6

(1.4–14.6)

1.9

(1.2–2.5)

1.8

(0.7–7.2)

12

(4.3–35)

0.003*

ACR1 [mg/mmol], median (25th –75th)

0.8

(0.5–1.6)

0.7

(0.4–1.3)

0.7

(0.4–1.3)

1.3

(0.6–2.7)

0.143

ACR [mg/mmol], median (25th –75th)

1.1

(0.5–3.6)

0.8

(0.4–1.3)

1.0

(0.4–2.6)

2.1

(0.7–6.7)

0.186

2

2

1
at admission; 1* at discharge; 2 1 year post stroke.
ACR – Albumin-to-creatinine ratio, hs-CRP – high sensitive C-reactive protein, mRS – modified Rankin Scale, n – number of patients, NIHSS – National Institutes of Health
Stroke Scale, SD – standard deviation, TG – triglycerides, WBC – white blood cells.
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Figure 1. A temporal profile of neurological and cognitive status and significant biochemical parameters over a 1-year poststroke
period. Data are given as mean (±SD) or median (minimum–maximum values).

discrimination ability, was 0.906 (0.827–0.986), which
meant that in almost 91% of all possible pairs of patients in
which one had a normal cognitive status and the other had
a cognitive impairment, the model would assign a higher
probability to the patient with cognitive impairment. The
optimal sensitivity found was 75% and the specificity was
84%.
4. Discussion
Cognitive impairments are often seen after a stroke
(1,2,11). About half of the ischemic stroke patients
included in the present study who had not had prestroke
dementia and had no poststroke depression developed
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mild to moderate cognitive deficit in the first year after
the stroke. Similar results were reported by Serrano et al.
(11). Other researchers also reached the conclusion that a
cerebrovascular event may have a major detrimental effect
on cognition even in patients with a low baseline risk of
dementia (3).
The objective of the present study was to establish
important determinants of cognitive deficit that can be
evaluated immediately after stroke onset and may prove
useful in predicting cognitive decline in the first year after
the stroke. In addition, our aim was to follow up on the
dynamics of some biochemical parameters over a 1-year
poststroke period to determine whether there is any
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Table 2. Logistic regression model of factors predicting cognitive decline in the first year after stroke.

Variables

B

S.E.

Wald

d.f.

Sig.

Exp(B)

Age [years]

0.270

0.105

6.602

1

0.010

Sex

1.325

0.888

2.226

1

History of diabetes

–0.209

0.917

0.052

hs-CRP [mg/L]

0.173

0.070

Constant

–19.679

7.202

95% CI for EXP(B)
Lower

Upper

1.309

1.066

1.608

0.136

3.761

0.660

21.428

1

0.819

0.811

0.135

4.891

6.210

1

0.013

1.189

1.038

1.363

7.467

1

0.006

0.000

hsCRP – High sensitive C-reactive protein, d.f. – degrees of freedom, Exp(B) – odds ratio, S.E. – standard error, Sig. – significance, CI
– confidence interval.
Cognitive status: normal [MMSE = 0], cognitive impairment [MMSE = 1]. Sex: male = 1, female = 2. History of diabetes: yes = 1, no = 2.

difference in their values found in cognitively impaired
and cognitively intact patients.
Our results demonstrated that the patients who
developed mild to moderate cognitive impairment were
advanced in age and predominantly females, with low
levels of education, a history of diabetes, and high serum
hs-CRP levels on admission. Moreover, patients who
developed cognitive deterioration had a more active
immune status than those who remained cognitively
normal, resulting in higher WBC and granulocyte counts
over the 1-year poststroke period. Among the significant
determinants, serum hs-CRP and age were the only
independent predictors of cognitive decline 1 year after a
stroke.
In our study, the effect of lesion localization on the
cognitive status 1 year after a stroke was not significant.
This could be attributed to the fact that most of the patients
(83%) had hemispheric infarctions. The relationship
between lesion localization and long-term cognitive
decline is worth attention in future research.
A distinctive feature of inflammatory reaction in the
brain is the activation of resident microglia accompanied
by the recruitment and infiltration of peripheral
inflammatory cells. The activation of inflammatory cells
is known to stimulate the production of proinflammatory
factors that in turn stimulate the liver synthesis of CRP
(12). Such conclusions were supported by the correlations
that we established between the serum hs-CRP levels and
the WBC (Rs = 0.301, P = 0.040) and granulocyte (Rs =
0.389, P = 0.007) counts on admission. On the other hand,
microalbuminuria, a marker of endothelial dysfunction
of the kidneys or brain vessels, is thought to be caused
by oxidative processes and inflammation. Some data
published in the literature have indicated an association
between albuminuria, markers of inflammation, and
cognitive decline. We also found a positive correlation

between the hs-CRP levels and the albumin-to-creatinine
ratio within the first 48 h of stroke onset (Rs = 0.465, P =
0.001). Moreover, this ratio remained high in the cognitively
impaired group during the whole follow-up period even
after adjustment for sex and age. The finding also suggests
the existence of persistent endothelial dysfunction in the
cognitively impaired subjects. Our results demonstrated
that stroke-induced acute inflammation was the major
cause of long-term cognitive deterioration since the
relationship between hs-CRP levels and cognition was
independent of the vascular risk profile of the patients.
Postischemic inflammation is a dynamic process
comprising a complex network of different interactions
that develop against the background of concomitant
vascular risk factors. The risk factors themselves also
contribute to cognitive impairment, and their effect could
be mediated by low-grade chronic inflammation.
Age was found to be an independent predictor of
cognitive decline in the first poststroke year. This finding is
in accordance with previous studies, which have established
that age predicts poststroke cognitive dysfunction (13,14).
A variety of age-related functional changes in the brain
may reduce its capacity to compensate for stroke-initiated
vascular injury (15). On the other hand, aging itself is
normally accompanied by memory impairment (16). A
likely cause of age-related cognitive decline could be the
degenerative processes in the brain that develop against
a background of chronic subclinical inflammation (17).
Indeed, enhanced serum hs-CRP levels are associated with
cognitive deterioration in the elderly without a history
of cerebrovascular events (18). The results of our study
show that the combined effect of factors such as aging and
inflammation could significantly increase the susceptibility
of the brain to further cerebral damage after stroke.
Aging, with its accompanying chronic inflammation,
and infarction, which initiates acute inflammation, have
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similar vascular pathophysiologies. Together they possibly
exert additive effects on cognitive decline.
We found that the level of education, sex, and history
of diabetes mellitus were significant determinants
of cognitive decline 1 year after stroke, as shown in
previous studies (13,14). However, these did not emerge
as independent predictors of long-term cognitive status.
Generally, a low education level is associated with
decreased functional cognitive reserve, and it also may
have an impact on lifestyle and risk factor profile. On the
other hand, the women in the study were more likely to
have cognitive impairment 1 year after the stroke, which
is consistent with data previously published (19). A
likely explanation of this observation is the fact that the
immune system of elderly women is more active than that
of men of the same age, as judged by the levels of some
cytokines in the circulation (17). Our data indicated that
a history of diabetes correlated with both the functional
and the cognitive outcome in patients (χ2 = 9.265, Р =
0.05). Previous studies have even identified diabetes as
an independent predictor of poststroke dementia, which
could not be confirmed in this study. Obviously, some
factors such as inflammation and diabetes are strongly
interdependent. Other stroke risk factors, including
alcohol abuse, smoking, and a previous stroke, were not

found to influence the poststroke cognitive status, but
these could increase the risk for cognitive deterioration by
increasing the risk of stroke.
The present study has several limitations. 1) Although
the MMSE is currently the most widely used cognitive
screening instrument, it has some weaknesses. A detailed
neuropsychological battery of tests may allow examining
the effect of stroke on a number of cognitive functions. 2)
Although the established predictive model was validated
using ROC analysis, the results are limited by the small
sample size. 3) Another limitation is that the parameters of
inflammation and endothelial dysfunction were measured
in the circulation, and these do not necessarily reflect local
brain processes.
In conclusion, we established that age and serum levels
of hs-CRP in the acute phase of stroke were independent
predictors of cognitive deterioration in the first year after
a stroke. Furthermore, patients who developed cognitive
deterioration demonstrated reactive immune statuses and
endothelial dysfunction. Together, aging and inflammation
may have the potential to increase brain susceptibility to
long-term cognitive impairment after stroke. The role of
inflammation in poststroke cognitive impairment needs to
be further explored in large-scale prospective studies.
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